A Living & Adaptive
Intelligence Engine
A Living & Adaptive
Intelligence Engine
Our Cross-Modality Intelligence Engine continuously learns from imaging, molecular, and clinical data through proprietary foundation models, large language models, and biology-tuned analysis engines. It empowers biopharma & clinical teams with advanced capabilities for biomarker discovery, mechanism of action exploration, and indication expansion by deriving meaningful insights across modalities, enabling more predictive, insight-driven workflows that optimize trial design and improve therapeutic success.

A transformative SaaS platform delivering advanced capabilities for biomarker discovery, indication expansion, and patient identification across multiple therapeutic areas.
At its core, is our proprietary Cross-Modality Intelligence Engine, that uncovers insights across histopathology, gene expression, mutational profiles, and clinical records to advance biomarker discovery, improve patient identification and stratification, and optimize trial design, even from small clinical cohorts.





















Our Medical Advisory Board
World-Leading Experts at the Forefront of Healthcare & Precision Oncology






David Agus, MD.
Founding CEO
Ellison Medical Institute

Natasha Leighl, MD.
Princess Margaret Cancer Centre, University of Toronto

Christian Rolfo, MD., PhD.
The Ohio State University Comprehensive Cancer Center

Ross Camidge, MD., PhD. University of Colorado Cancer Center, Aurora, Colorado

Tony Mok, MD.
Dept. of Clinical Oncology
Chinese University, Hong Kong